First-Line Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma – The ASCO Post
First-Line Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma By The ASCO Post StaffDecember 10, 2019 On April 19, 2019, pembrolizumab was approved for use in combination with the small-molecule tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell…